Open AccessFactor XIII and Tranexamic Acid But Not Recombinant Factor VIIa Attenuate Tissue Plasminogen Activator–Induced Hyperfibrinolysis in Human Whole Blood
Author(s) -
Daniel Dirkmann,
Klaus Görlinger,
Caroline Gisbertz,
Fabian Dusse,
Jürgen Peters
Publication year - 2012
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1213/ane.0b013e31823b6683
Subject(s) - hyperfibrinolysis , thromboelastometry , fibrinolysis , medicine , thromboelastography , factor xiii , thrombelastography , platelet , tranexamic acid , coagulation , plasminogen activator , whole blood , tissue plasminogen activator , immunology , pharmacology , fibrinogen , surgery , blood loss
Hyperfibrinolysis is a pathological state that often results in depletion of coagulation factors and platelets and can contribute to bleeding. Factor XIII (FXIII) and thrombin activatable fibrinolysis inhibitor have key roles in protecting clots against fibrinolysis. We tested the hypotheses that FXIII concentrate, prothrombin complex concentrate (PCC), recombinant factor VIIa (rFVIIa), and tranexamic acid (TA) inhibit fibrinolysis to different degrees, and that platelets contribute to antifibrinolysis.